Gamida Cell's Blood Cancer Candidate Shows Encouraging Anti-Tumor Activity In Heavily Pretreated Patients
Portfolio Pulse from Vandana Singh
Gamida Cell Ltd (NASDAQ:GMDA) has released early data from an ongoing Phase 1 study of its natural killer (NK) cell therapy candidate GDA-201, showing encouraging anti-tumor activity in heavily pretreated patients with CD20-positive non-Hodgkin lymphoma. Preliminary results showed marked shrinkage of target lesions in five patients. No dose-limiting toxicities were reported. The company's shares are up 6.01% at $0.94 during the premarket session.
October 17, 2023 | 12:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gamida Cell's early data from Phase 1 study of GDA-201 shows promising results, leading to a rise in the company's stock price.
The positive early data from the Phase 1 study of Gamida Cell's GDA-201 indicates potential success in the treatment of CD20-positive non-Hodgkin lymphoma. This has led to increased investor confidence, reflected in the rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100